title: Deferoxamine therapy for intracerebral hemorrhage.
abstract: Intracerebral hemorrhage (ICH) is a subtype of stroke with very high mortality. Experiments have indicated that clot lysis and iron play an important role in ICH-induced brain injury. Iron overload occurs in the brain after ICH in rats. Intracerebral infusion of iron causes brain edema and neuronal death. Deferoxamine, an iron chelator, is an FDA-approved drug for the treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent anemia. Deferoxamine can rapidly penetrate the blood-brain barrier and accumulate in the brain tissue in significant concentration after systemic administration. We have demonstrated that deferoxamine reduces ICH-induced brain edema, neuronal death, brain atrophy, and neurological deficits. Iron chelation with deferoxamine could be a new therapy for ICH.
authors.affiliation: Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109-2200, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Hua
authors.forename: R F
authors.initials: RF
authors.lastname: Keep
authors.forename: J T
authors.initials: JT
authors.lastname: Hoff
authors.forename: G
authors.initials: G
authors.lastname: Xi
mesh_terms: D000818:Animals; D001929:Brain Edema / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D016923:Cell Death; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D017262:Siderophores / Q000627:therapeutic use*
chemical_list: D017262:Siderophores; D003676:Deferoxamine